Cargando…
P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431364/ http://dx.doi.org/10.1097/01.HS9.0000971168.59900.67 |
| _version_ | 1785091182963982336 |
|---|---|
| author | Timmerman, John Lavie, David Johnson, Nathalie Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Luigi Zinzani, Pier Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Herrera, Alex F. |
| author_facet | Timmerman, John Lavie, David Johnson, Nathalie Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Luigi Zinzani, Pier Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Herrera, Alex F. |
| author_sort | Timmerman, John |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431364 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104313642023-08-17 P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT Timmerman, John Lavie, David Johnson, Nathalie Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Luigi Zinzani, Pier Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Herrera, Alex F. Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431364/ http://dx.doi.org/10.1097/01.HS9.0000971168.59900.67 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Timmerman, John Lavie, David Johnson, Nathalie Avigdor, Abraham Borchmann, Peter Andreadis, Charalambos Bazargan, Ali Gregory, Gareth Keane, Colm Tzoran, Inna Vucinic, Vladan Luigi Zinzani, Pier Marceau West, Rachel Pillai, Pallavi Marinello, Patricia Herrera, Alex F. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT |
| title | P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT |
| title_full | P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT |
| title_fullStr | P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT |
| title_full_unstemmed | P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT |
| title_short | P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT |
| title_sort | p1068: updated results from an open-label phase 1/2 study of favezelimab in combination with pembrolizumab in patients with relapsed or refractory classical hodgkin lymphoma after anti–pd-1 treatment |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431364/ http://dx.doi.org/10.1097/01.HS9.0000971168.59900.67 |
| work_keys_str_mv | AT timmermanjohn p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT laviedavid p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT johnsonnathalie p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT avigdorabraham p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT borchmannpeter p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT andreadischaralambos p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT bazarganali p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT gregorygareth p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT keanecolm p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT tzoraninna p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT vucinicvladan p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT luigizinzanipier p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT marceauwestrachel p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT pillaipallavi p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT marinellopatricia p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment AT herreraalexf p1068updatedresultsfromanopenlabelphase12studyoffavezelimabincombinationwithpembrolizumabinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomaafterantipd1treatment |